This aerial photo taken on Jan. 1, 2023 shows a night view of the commercial area around Tianhe Road in Guangzhou, south China's Guangdong Province. (Xinhua/Liu Dawei)
* Life is returning to normal and mobility is rebounding as China's COVID-19 prevention and control has entered a new stage -- a boon for world economy.
* Deliberately distorting the adjustment of China's anti-COVID-19 policies highlights the double standard and hypocrisy of some in the West.
* China has made rural areas a focal point in the country's current COVID response, boosting medical capacities and providing timely support. Chinese medical institutions at all levels are taking all the necessary measures to increase resources and personnel. The reality is that they are busy but functioning smoothly.
BEIJING, Jan. 7 (Xinhua) -- Life is returning to normal and mobility is rebounding as China's COVID-19 prevention and control has entered a new stage -- a boon for world economy.
However, some Western media ignore the facts, choosing instead to apply double standard and even spread misinformation, while making unwarranted accusations against China's epidemic fight, confusing the public and misleading the world as a consequence. However, in the face of facts and data, these lies are evident and untenable.
FALLACY 1: "NEW COVID POLICY BRINGS CHAOS"
The real situation is: Grand Tang Dynasty Ever Bright City, a commercial pedestrian street in Xi'an of Shaanxi Province, was packed with people; residents in Shijiazhuang of Hebei Province and Wuhan of Hubei Province released balloons; locals in Xiangtan, Hunan Province, enjoyed a fireworks show during the New Year celebrations. "Seeing so many people celebrating the New Year together, I was nearly moved to tears," one netizen wrote.
Passengers are pictured in Shenzhen North Railway Station during the Spring Festival travel rush in Shenzhen, south China's Guangdong Province, Jan. 7, 2023. (Xinhua/Mao Siqian)
More than 50 million people traveled in China during the New Year holiday. On Jan. 1, 10,640 cinemas opened for business nationwide, a new high in nearly 10 months. Many people are planning to return to their hometowns for family reunions or travel in the forthcoming Spring Festival. Bookings of domestic air tickets and hotels have increased significantly.
Traffic is getting heavier, more factories are running at full capacity, while the construction of new projects is underway.
China has put the people first and put life first all along, with prevention and control measures adjusted and optimized in light of evolving situations, and done its utmost to protect people's lives and health.
So far, the focus of China's epidemic prevention and control has shifted from preventing infections to beefing up treatment of severe cases. From coordinating drug production to strengthening the treatment of severe cases, and from promoting vaccination to speeding up the resumption of production, China has effectively coordinated epidemic prevention and control and economic and social development needs.
A community worker (L) explains a COVID-19 prevention and care package to a resident in Yangfangdian Subdistrict of Haidian District in Beijing, capital of China, Dec. 27, 2022. (Xinhua/Ren Chao)
Under the assistance of the government, pharmaceutical enterprises are running at full capacity. China has also optimized the circulation of drugs, testing reagents and protective goods for better epidemic control. Authorities in many regions provided the elderly with free "health kits," which usually include fever drugs and other anti-epidemic items.
By the middle of December 2022, more than 3.47 billion COVID-19 vaccine doses had been administered on the Chinese mainland, with over 90 percent of the population fully vaccinated. A total of 86.6 percent of people aged 60 or above had been fully vaccinated and the rate among people aged 80 or older was 66.4 percent. China also vowed to further ramp up vaccination efforts aimed at the elderly.
Wang Huaqing, an expert from the Chinese Center for Disease Control and Prevention (China CDC), said the COVID-19 vaccines currently used in China are effective in preventing severe conditions and deaths. Data shows that during the epidemic outbreak period from March to June last year in Shanghai, compared with those who had not been vaccinated, the death risk of those over 60 who had received the booster doses of vaccines decreased by 98.08 percent.
The China CDC has also strengthened the monitoring of virus mutation nationwide. Each provincial-level region carries out genome sequencing and analysis every week and uploads the data in time in order to dynamically monitor virus subtypes.
FALLACY 2: "CHINA'S COVID RESPONSE A FAILURE"
During the past three years, China launched a war against COVID-19, effectively handled more than 100 cluster outbreaks, and protected the lives and health of more than 1.4 billion people to the greatest extent.
Every country would and should adjust its anti-COVID-19 policies according to the changing situation of the epidemic and go through periods of adaptation following such adjustments.
A medical worker injects a booster shot of COVID-19 vaccine for a resident at Aoyuncun Subdistrict in Chaoyang District, Beijing, capital of China, July 13, 2022. (Xinhua/Ju Huanzong)
The pathogenicity and virulence of the Omicron strain have weakened significantly, while China's medical treatment, pathogen detection and vaccination levels have all improved significantly -- which means that it is indeed scientific, timely and necessary to proactively optimize anti-epidemic measures.
The elderly are the key population group being targeted by health services. During the battle in Wuhan in early 2020, medical workers cured more than 3,600 COVID-19 patients over the age of 80. In the past three years, a number of infected centenarians have recovered and been discharged from hospitals. Similar stories are still unfolding during this new wave of infections in China.
Tian, a 100-year-old woman from Hefei, Anhui Province, was diagnosed with novel coronavirus infection after she showed symptoms such as fever and coughing for three days, and was sent to the hospital by her family.
Her doctor said that fortunately, Tian had been vaccinated and showed no severe symptoms such as chest tightness and asthma, although she had some underlying health issues. After 11 days of treatment including anti-virus, anti-infection, improved immunity and nutritional support, she was discharged from the hospital.
China has managed to keep its severe cases and death rates of COVID-19 among the lowest in the world. Deliberately distorting the adjustment of China's anti-COVID-19 policies highlights the double standard and hypocrisy of some in the West. If China's COVID-19 response failed, what about some countries where the death toll far exceeds that of China? In fact, the label of failure should be attached to those countries whose incompetence, inaction and chaos in epidemic response had caused their people to suffer.
Striving to effectively coordinate the epidemic response with economic and social development, China had won the tough battle against poverty on schedule and finished building a moderately prosperous society in all respects, getting off to a good start in the 14th Five-Year Plan period (2021-2025), and the average life expectancy of Chinese people increased from 77.3 years to 78.2 years.
Some Western media rarely reflect profoundly on the chaotic COVID-19 situations in their own countries. But when it comes to China, they always hold a stereotypical view and focus only on finding fault, which underlines their attempt to distort, exaggerate and fabricate.
"In fact, China has innovated control methods, improved them, and demonstrated their efficacy by saving millions of lives," said Josef Gregory Mahoney, a professor of politics and international relations at East China Normal University. The professor noted that some countries look at China through a perverse lens: they fail to acknowledge the country's successes because they politicize everything about China ideologically.
FALLACY 3: "CHINA'S ECONOMIC OUTLOOK IS DIM"
China's optimized COVID-19 response has triggered a lot of ups and downs in terms of predicting the impact on the Chinese economy. A topsy-turvy time and a drag on global growth were among the typical labels foreign pessimists put on the future of the Chinese economy.
Some foreign naysayers, bothered by the "unfortunate side-effects" of China's recovery, even warned that China's reopening may burden the rest of the world, not with higher growth, but with higher levels of inflation or interest rates.
Are the prospects of China's economic recovery bright or dim?
Over the past three years, China has effectively handled the impact of five rounds of global pandemic outbreaks.
Balancing its epidemic response and economic and social development, China not only emerged as the first major economy to return to growth, but also maintained an average annual growth rate of about 4.5 percent, significantly higher than the world average.
In 2022, China was expected to boost its GDP to over 120 trillion yuan (17.41 trillion U.S. dollars). Its grain output stayed above 650 million tonnes for the eighth consecutive year. In the first 11 months of last year, 1.16 trillion yuan of foreign investment went into the country, exceeding the level of 2021.
At the tone-setting Central Economic Work Conference in December, Chinese leaders aimed to promote overall recovery and improvements in the country's economic performance this year.
From a global perspective, China's strengths are also clear. Its economy accounts for 18.5 percent of the world's total and serves as an important growth driver. Its foreign exchange reserves top the world, helping ensure the stability of its currency the yuan and financial security.
An employee works at an automobile company in Yuyao, east China's Zhejiang Province, Jan. 5, 2023. (Xinhua/Huang Zongzhi)
Businesses remain optimistic about the Chinese market. Axel Weber, chairman of the Institute of International Finance, said the Chinese economy remains a massive opportunity for Western companies.
The capacity of Foxconn's plant in Zhengzhou, Henan Province has returned to its peak season levels with about 200,000 workers, shaking off the impact of the epidemic.
"Now, all the production lines of Foxconn's plant in Zhengzhou are running normally, and we have taken various measures to motivate our employees," said Wang Xue, deputy general manager of Foxconn Technology Group.
The optimized response China adopted to deal with COVID-19 is expected to have a "J-curve effect" on the economy, said Han Wenxiu, executive deputy director of the office of the Central Committee for Financial and Economic Affairs. "It may cause disruptions to the economy in the short-term, but from the perspective of a whole year outlook, it is a boon."
FALLACY 4: "PATIENTS GOING SHORT OF MEDICINE AND TREATMENT"
The truth is: Chinese medical institutions at all levels are taking all the necessary measures to increase resources and personnel. The reality is that they are busy but functioning smoothly.
The First Affiliated Hospital of Harbin Medical University in Harbin, Heilongjiang Province, has received over 140 critically ill COVID-19 patients in recent days.
"Many doctors continued working and caring for patients while they themselves were ill, and we are going all out to save every severe patient," said Yu Kaijiang, president of the hospital.
The hospital has increased the number of intensive care beds from 132 to 143, and has actively sought ventilators from various channels, with a group of 60 nurses working shifts to cope with the surge in COVID-19 patients.
As of Dec. 25, 2022, the number of fever clinics in second-grade hospitals and above had reached 16,000 in China, and the number of such clinics in grassroots medical institutions totaled 41,000.
China is one of the largest producers of fever medicines, and its total production capacity is sufficient to meet demand.
The daily output of ibuprofen and acetaminophen, two key antipyretic analgesics, had reached 202 million tablets and 190 million tablets, respectively, by the end of 2022, said Wang Jiangping, vice minister of industry and information technology.
Staff members pack medicines at a pharmaceutical company in central China's Hunan Province, Dec. 19, 2022. (Xinhua/Chen Sihan)
"We quickly adjusted the variety of drugs we produce, increased the output, and went all out to ensure the market demand of antipyretic and analgesic drugs such as ibuprofen and aspirin," said Kou Zuxing, deputy general manager of Shandong Xinhua Pharmaceutical Co., Ltd., based in the city of Zibo, Shandong Province.
As the world's leading producer of ibuprofen materials, the company's tablet capacity has been raised threefold, while its ibuprofen production has climbed to more than 10,000 tablets a minute.
The total number of beds in second-grade medical institutions and above in China is 5.616 million, and the utilization rate of beds has fluctuated around 60 percent recently. The total number of intensive care beds in China has reached 150,000, meaning there are 10.6 beds per 100,000 people. The country has a reserve of 70,000 adaptable intensive care units (ICU).
As for the equipment used to treat COVID-19 patients, there were 151,100 hemodialysis units, 19,700 continuous renal replacement therapy units, 2,300 extracorporeal membrane oxygenation machines, and over 192,000 invasive and non-invasive respirators in second-grade hospitals and above as of late December.
"Overall, China has adequate medical resources, including beds and equipment, to meet the demand of patients in critical condition," said Jiao Yahui, head of the Bureau of Medical Administration under the National Health Commission (NHC).
China will put more effort into tracking the spread of the epidemic, strengthen coordination between cities and regions, and upgrade and expand relevant resources to meet people's medical demands, Jiao said.
FALLACY 5: "'DARK COVID WINTER' FOR VILLAGERS"
The truth is: China has made rural areas a focal point in the country's current COVID response, boosting medical capacities and providing timely support.
The country's 23,000 county-level medical institutions, 35,000 township hospitals and 599,000 village clinics have formed a closely collaborative and efficient health protection system so that rural patients can enjoy tiered, timely and convenient medical services.
Rural doctors visit local households to provide medical support in Jiwei Town of Huayuan County, central China's Hunan Province, Dec. 29, 2022. (Photo by Jian Biao/Xinhua)
"At present, medicines for fever and cough relief have been prepared, which can meet the needs of the whole village for two months," said Fu Xiangpeng, a doctor from the mountainous Liguanying Village in Zhenxiong County, southwest China's Yunnan Province. "People with mild symptoms can go to village clinics to get drugs, and medicine will be sent to the elderly people with difficulties."
Jiao Yahui, the NHC official, said that drug supply must be ensured in rural areas and cover the Spring Festival travel rush period or even longer. More importantly, severe cases should be transferred to at least county-level hospitals.
Jiao said that counties and towns had been ordered to prepare standby vehicles to transport severe patients as quickly as possible. Internet hospitals and roving medical teams have also ramped up rural medical capacity.
FALLACY 6: "OFFICIAL COVID DEATH TOLL UNRELIABLE"
The fact is: China has always published information on COVID-19 deaths and severe cases in the spirit of openness and transparency.
The global criteria for judging COVID deaths are divided into two categories. Some countries count only cases of people who tested positive for COVID-19 and died of respiratory failure induced by the virus. Other countries count all the deaths as COVID deaths as long as the deceased had tested positive for the virus in the past 28 days.
Since 2020, China has been adopting the first criterion, counting a death from respiratory failure caused by the novel coronavirus after a positive COVID-19 test as a COVID death.
China has also published cases in which the patients were infected by novel coronavirus but the direct causes of the death were underlying diseases. In such cases, the causes of the death were attributed to underlying diseases.
China canceled mass nucleic acid tests following the adjustments to its COVID response policy, making it very difficult to obtain accurate data on the infection caseload in the first place. This is the normal de facto situation in other countries.
Wu Zunyou, chief epidemiologist of the China CDC, pointed out that there is a calculation method called "excess death" in the field of public health, which can evaluate possible underestimation. Regarding the "excess death" that may be caused by this wave of epidemic, the team is already doing the relevant work and will release the results later.
China's war against COVID-19 is still underway, and victory shall come for the 1.4 billion Chinese people. The fallacies and their fabricators will prove to be wrong. ■
